Today: 9 June 2026
Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade
30 December 2025
1 min read

Why Qualys stock is sliding today: QLYS lags cybersecurity peers in late-year trade

NEW YORK, December 30, 2025, 15:41 ET — Regular session

  • Qualys shares were down about 2.5% in afternoon trading, after touching a session low.
  • Cybersecurity peers were little changed, leaving QLYS as a notable underperformer in the group.
  • Investors are weighing year-end positioning and fresh Federal Reserve signals as 2026 data and policy dates come into view.

Qualys Inc shares fell 2.5% to $133.93 in afternoon trading on Tuesday, after dropping as much as 4.2% earlier in the session. The stock closed at $137.34 on Monday.

The decline landed as U.S. equities stayed range-bound in holiday-thin conditions, with technology and financial shares among the drags. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

That matters for Qualys because lighter year-end liquidity can exaggerate moves in single names, especially in software stocks where positioning has been crowded at times. With few fresh company headlines, traders tend to lean harder on macro cues and sector sentiment.

Cybersecurity peers were mostly steady: CrowdStrike was up 0.1%, Palo Alto Networks added 0.1% and Fortinet slipped 0.4%. The Invesco QQQ Trust, a widely used proxy for Nasdaq-100 tech exposure, was down 0.1%.

The company’s last major update to investors came with its Nov. 4 results, when it said third-quarter revenue rose 10% to $169.9 million and issued fourth-quarter revenue guidance of $172 million to $174 million. Qualys also guided for fourth-quarter non-GAAP net income per share of $1.73 to $1.80 and lifted its full-year revenue outlook to $665.8 million to $667.8 million.

Qualys’ newsroom lists that Nov. 4 earnings release as its most recent press update, underscoring how quickly the narrative can shift from company-specific fundamentals to tape-reading in the final sessions of the year.

Non-GAAP results are adjusted figures companies use to strip out certain items they consider non-core, such as stock-based compensation and amortization. Investors often track the gap between GAAP and non-GAAP profit to judge how much earnings power depends on adjustments.

On the macro front, the Federal Reserve’s latest meeting minutes showed a more divided debate over the December rate decision, with some policymakers describing the choice as “finely balanced.” The minutes also pointed investors to a coming catch-up in U.S. data, with December jobs and consumer price reports due in early January. Reuters

The next Fed policy meeting is scheduled for Jan. 27-28, according to the central bank’s calendar. That date is now a key waypoint for markets trying to map the rate path into 2026.

For Qualys, traders will be watching whether the stock can stabilize above Tuesday’s intraday low into the close, and whether it can reclaim Monday’s closing level on any bounce. Bigger swings late in the day would not be unusual in thin trading.

Investors will also keep an eye on how management’s fourth-quarter targets line up with demand signals across enterprise security spending. Subscription renewals, customer expansion and operating margin trends remain the core read-throughs when the next results arrive.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Previous Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Next Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Go toTop